andy, Author at BaseLaunch

All

Alentis appoints Alberto Toso Chief Scientific Officer

Basel, Switzerland – 29 April, 2024, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today…

andy06.05.2024

All

Our partnership with CSL

BaseLaunch is excited to announce the extension of the partnership with CSL, a global biotech leader. Together, we're committed to driving innovation in healthcare. CSL’s…

andy18.03.2024

All

We welcome VISCHER as our new domain partner

We are pleased to announce a partnership with VISCHER, a respected Swiss law firm known for its commitment to providing startups, entrepreneurs and investors with…

andy12.03.2024

Uncategorized

Podcast: How to build a compelling pitch deck for early stage ventures

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch the attention of investors.For biotech…

andy07.03.2024

All

KPMG renews partnership with BaseLaunch

We are delighted to announce that KPMG, is continuing its partnership with BaseLaunch to help support cutting-edge early-stage biotechs to achieve financing and grow their…

andy04.03.2024

All Features

FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund

FimmCyte, a pioneering women's health biotech, announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences Fund (LSF). FimmCyte’s…

andy29.02.2024

All Features

Synendos Therapeutics granted EMA clinical trial authorisation

BASEL, Switzerland, 18 January 2024 - Synendos Therapeutics AG, a world leader in innovative Endocannabinoid System (ECS) treatments, today announces that it has received approval…

andy18.01.2024

All Features

William Pao joins Alentis Therapeutics as independent board member

Basel, Switzerland – Alentis Therapeutics , a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that Dr. William…

andy09.01.2024

All Features

Novo Nordisk becomes a BaseLaunch partner

Novo Nordisk has become the latest partner to join BaseLaunch. Novo Nordisk joins other world-class pharma, venture fund and biotechnology partners - Roche, Johnson &…

andy18.12.2023

All Features

Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM

Basel, Switzerland, 13 December, 2023 – Engimmune Therapeutics AG (“Engimmune”), a world-class developer of soluble T-cell receptor drugs (‘TCRs’) to treat solid tumours, is pleased…

andy13.12.2023

andy

Alentis appoints Alberto Toso Chief Scientific Officer

Our partnership with CSL

We welcome VISCHER as our new domain partner

Podcast: How to build a compelling pitch deck for early stage ventures

KPMG renews partnership with BaseLaunch

FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund

Synendos Therapeutics granted EMA clinical trial authorisation

William Pao joins Alentis Therapeutics as independent board member

Novo Nordisk becomes a BaseLaunch partner

Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us